News >

Unlocking the Potential of Immunotherapy in Breast Cancer

Andrew D. Smith
Published: Wednesday, Mar 21, 2018

Dr. Elizabeth A. Mittendorf
Elizabeth A. Mittendorf, MD, PhD
Recent immunotherapy trials have produced mixed results in patients with breast cancer. A pair of trials that used checkpoint inhibitors as monotherapy reported lackluster overall response rates (ORRs). Trials that paired immunotherapy with chemotherapy, on the other hand, fared better, and there are promising hints that immunotherapies combined with some targeted agents might also work better than immunotherapy alone.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances In™ Tumor Testing: Interpreting Genomic Profiles to Optimize Breast Cancer TreatmentJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication